Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -316.63%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-372.31%
RETURN ON EQUITY (ROE) AVG 3Y
-423.57%
RETURN ON EQUITY (ROE) AVG 5Y
-385.16%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ensysce Biosciences, Inc.
Market Cap
$6.44M
Return on Equity (ROE)
N/A
TTM Avg
-372.31%
3Y Avg
-423.57%
5Y Avg
-385.16%
Market Cap
$6.34M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$6.72M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
Market Cap
$6.74M
Return on Equity (ROE)
-54.09%
TTM Avg
-388.62%
3Y Avg
-105.04%
5Y Avg
-44.72%
Market Cap
$6.76M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$6.10M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
Market Cap
$6.10M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$6.09M
Return on Equity (ROE)
105.35%
TTM Avg
0.10%
3Y Avg
-37.77%
5Y Avg
-33.57%
Market Cap
$6.03M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.44M | N/A | -372.31% | -423.57% | -385.16% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -143.54% | -132.34% | -104.07% | -91.90% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -227.37% | -118.13% | -87.25% | -55.09% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -54.09% | -388.62% | -105.04% | -44.72% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -108.00% | -445.77% | -254.63% | -239.85% |
| Femasys Inc. (FEMY)vs › | $6.10M | -304.78% | -566.96% | -321.57% | -251.82% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -87.12% | -90.45% | -143.11% | -272.17% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 105.35% | 0.10% | -37.77% | -33.57% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -92.44% | -28.72% | 10.69% | 23.75% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -370.16% | -148.31% | -87.53% | -43.20% |
ROE
N/A
ROA
-426.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -316.63% |
| 2025-09-30 | -911.82% |
| 2025-06-30 | -194.20% |
| 2025-03-31 | -223.55% |
| 2024-12-31 | -215.37% |
| 2024-09-30 | -114.73% |
| 2024-06-30 | -623.79% |
| 2024-03-31 | -307.85% |
| 2023-09-30 | -848.42% |
| 2023-06-30 | -479.35% |
| 2021-06-30 | -1.09% |
| 2020-09-30 | -28.00% |
| 2020-06-30 | -50.60% |
| 2020-03-31 | -10.26% |
| 2019-12-31 | 0.44% |
| 2019-09-30 | 57.24% |
| 2019-06-30 | 59.00% |
| 2019-03-31 | 49.84% |
| 2018-12-31 | 42.44% |
| 2018-09-30 | 27.45% |
